MDST Medicsight

    RNS Number : 1085B
  Medicsight Plc
  12 August 2008
   


 Press Release  12 August 2008

    Medicsight Plc

    ("Medicsight" or "the Company")

    DIRECTORS BUY 310,500 SHARES


    Medicsight (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in
the early detection and diagnosis of disease, has today been notified that on 11 August 2008, Executive Directors Tim Paterson-Brown, David
Sumner and Allan Rowley collectively purchased 310,500 ordinary shares of the Company at an average price of 42 pence per share.

    Following these purchases, the Executive Directors' interests (either directly or indirectly) in ordinary shares are set out below:

                        Number of ordinary shares  Total ordinary  % of issued
                                        purchased         shares:        share
                                                                      capital:
 Tim Paterson-Brown                       110,000         110,000        0.07%
 David Sumner                             118,500         118,500        0.08%
 Allan Rowley                              82,000          82,000        0.05%

    David Sumner, CEO, of Medicsight commented, "This is an exciting time for the CAD software market, we are seeing increased demand from
the large OEMs for intelligent software that will add value to their product offering.  We look forward to driving the Company forward and
delivering against our corporate objectives. This share purchase reflects our collective commitment to Medicsight and our belief that this
continues to represent a very attractive investment."

    For further information:
 Medicsight plc
 David Sumner     +44 (0)20 7605 7950
                  www.medicsight.com 
 Nomura Code
 Jonathan Senior  +44 (0) 20 7776 1219 
 Juliet Thompson  +44 (0) 20 7776 1204

    Media enquiries:
 Abchurch
 Stephanie Cuthbert/Simone Alves        +44 (0) 20 7398 7700
 stephanie.cuthbert@abchurch-group.com  www.abchurch-group.com

    Notes to editors 
    Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software
for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the
colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD
software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data.
Medicsight's ColonCAD* and LungCAD* software products are seamlessly integrated with the advanced 3D visualisation workstations of several
industry-leading imaging equipment partners.

    About Computer-Aided Detection
    With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing
challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations
generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due
to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious
regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is
critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful
treatment and a positive therapeutic outcome. 


    About Medicsight's CAD software
    Medicsight's ColonCAD* and LungCAD* software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically
highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such
as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

    Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The
integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of
demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users
to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

    Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product
related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product
development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to
develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDSSFLFMFSASEIA

Medicsight (LSE:MDST)
Historical Stock Chart
From Sep 2024 to Oct 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Oct 2023 to Oct 2024